Business Context and Reporting Period
Capstone Therapeutics Corp. (the filing entity; the request metadata identifies Capstone Holding Corp.) filed this unaudited Form 10-Q for the quarter ended March 31, 2018. The company is a biotechnology business developing Apo E mimetic peptide AEM-28 and analogs through its approximately 60%-owned joint venture, LipimetiX Development, Inc. Prior product platforms, Chrysalin and AZX100, have been discontinued. The company operates primarily through a virtual model and has no revenue-producing operations following the 2003 sale of its Bone Device Business.
Financial Performance and Position
| Metric | Three months ended March 31, 2018 | Three months ended March 31, 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| General and administrative expense | $229,000 | $113,000 |
| Research and development expense | $301,000 | $267,000 |
| Total operating expenses | $530,000 | $380,000 |
| Interest and other expense, net | $60,000 | $15,000 |
| Net loss attributable to common stockholders | $587,000 | $387,000 |
| Basic and diluted loss per share | $0.01 | $0.01 |
| Cash used in operating activities | $470,000 | $212,000 |
At March 31, 2018, cash and cash equivalents were $805,000, including $300,000 held by the joint venture, compared with $1.275 million at December 31, 2017. Total current assets were $881,000 and current liabilities were $206,000. Secured debt and accrued interest, net of unamortized issuance costs, totaled $2.296 million. Stockholders’ equity was negative $1.464 million, compared with negative $879,000 at year-end 2017. No meaningful revenue or operating margin was reported because the company had no revenue.
Material Changes Versus the Prior Comparable Period
- General and administrative expense increased $116,000, primarily due to professional fees and audit-related timing.
- Research and development expense increased $34,000, although development activity remained limited while the company sought funding.
- Net loss increased $200,000, or approximately 52%, to $587,000.
- Interest and other expense increased $45,000, reflecting secured-debt interest, noncash interest, amortization of financing costs, and warrant-related expense.
- Operating cash burn increased $258,000 to $470,000.
- Cash declined $470,000 during the quarter, with no investing or financing cash flows reported.
- Accumulated deficit increased to $191.961 million from $191.374 million.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that the company and joint venture did not have sufficient funding at March 31, 2018 to continue additional material development activities. Additional capital is required to continue operations and to advance AEM-28 and its analogs through further clinical development. Potential funding sources include strategic or merger transactions, debt or equity offerings, joint development arrangements, asset or development-rights sales, and licensing transactions.
The financial statements were prepared on a going-concern basis. Management reported that prior funding had alleviated substantial doubt about the company’s ability to continue as a going concern, but additional funds remain necessary for the joint venture’s development goals and planned operations.
On May 2, 2018, after the quarter-end, LipimetiX entered into a sublicense agreement with Anji Pharmaceuticals covering China, Taiwan, and Hong Kong. The agreement provides for a $2.0 million initial payment, future royalties, and milestone payments; Anji is responsible for permitted development activities in the territory. The filing does not state when the initial payment will be recognized as revenue.
The company’s secured loan has principal of $2.428 million, bears interest at 6%, and matures October 15, 2020. Interest payments were deferred to maturity under a January 2018 amendment in exchange for warrants to purchase up to 6,321,930 shares at $0.075 per share; 984,301 shares were vested and exercisable at March 31, 2018. The lender, BP Peptides, owned approximately 34.1% of the company’s common stock.
The company has advanced $1.6 million to the joint venture. The revolving loan, including $60,000 of accrued interest, totaled $1.660 million at March 31, 2018 and was extended to July 15, 2020, subject to earlier repayment under specified funding conditions. Joint venture losses exceeded its capital accounts, and the company could absorb an additional $667,000 of losses allocated to noncontrolling interests if the joint venture does not continue as a going concern.
Principal risks include the need for additional funding, unfavorable clinical or preclinical results, regulatory delays or failure, competition, intellectual-property impairment, dependence on the joint venture and partners, the virtual operating model, and potential loss of OTCQB listing. Management reported no material legal proceedings and concluded that disclosure controls were effective.
Important Facts for Investors to Verify
- Confirm the filing entity name and reconcile it with the requested company name.
- Verify the timing and accounting treatment of the Anji sublicense’s $2.0 million initial payment.
- Assess available cash, quarterly cash burn, and the expected runway absent additional financing.
- Review the secured debt maturity, accrued interest, collateral, related-party ownership, and warrant dilution.
- Evaluate LipimetiX’s funding needs, development status, ownership structure, and potential allocation of additional losses to Capstone.
- Review whether future AEM-28 development can proceed without new financing or partnering arrangements.